Finally, in high-grade MDS, overexpression of DHX9, on the one hand, may promote excessive proliferation, and on the other hand, may produce apoptotic resistance to exogenous anti-tumor agents. This evidence concerns the gene DHX9 and myelodysplastic syndrome.